Neuroendocrine Tumor Research Foundation
Neuroendocrine Tumor Research Foundation maintains substantial assets with no reported officer compensation despite fluctuating revenues and occasional operational deficits.
EIN: 201945347 · Quincy, MA · NTEE: G123 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $5.3M |
| Total Expenses | $3.6M |
| Program Spending | 90% |
| CEO/Top Officer Pay | $21 |
| Net Assets | $15.5M |
| Transparency Score | 92/100 |
Is Neuroendocrine Tumor Research Foundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Neuroendocrine Tumor Research Foundation directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Neuroendocrine Tumor Research Foundation
Neuroendocrine Tumor Research Foundation (EIN: 201945347) is a nonprofit organization based in Quincy, MA, classified under NTEE code G123. The organization reported total revenue of $5.3M and total assets of $21.4M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Neuroendocrine Tumor Research Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Neuroendocrine Tumor Research Foundation is a mid-size nonprofit that has been operating for 21 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 9.2%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $3.2M |
| Total Expenses | $3.6M |
| Surplus / Deficit | $-384,216 |
| Total Assets | $20.6M |
| Total Liabilities | $5.1M |
| Net Assets | $15.5M |
| Operating Margin | -12.0% |
| Debt-to-Asset Ratio | 24.7% |
| Months of Reserves | 69.2 months |
Financial Health Grade: B
In 2023, Neuroendocrine Tumor Research Foundation reported a deficit of $384K with expenses exceeding revenue, holds 69.2 months of operating reserves (strong position), has a debt-to-asset ratio of 24.7% (moderate leverage).
Financial Trends
Over 13 years of filings (2011–2023), Neuroendocrine Tumor Research Foundation's revenue has grown at a compound annual growth rate (CAGR) of 9.2%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +3.9% | +2.6% | +0.5% |
| 2022 | -62.5% | -35.9% | -22.9% |
| 2021 | +76.5% | +35.3% | +11.9% |
| 2020 | -11.0% | -32.9% | +6.6% |
| 2019 | +13.3% | +5.4% | +17.1% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2005 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Neuroendocrine Tumor Research Foundation with a Mission Score of 92 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 7%
- programs: 90%
- fundraising: 3%
According to IRS 990 filings, Neuroendocrine Tumor Research Foundation allocates its expenses as follows: admin: 7%, programs: 90%, fundraising: 3%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $384K, with expenses exceeding revenue.
- Debt-to-asset ratio: 24.7%.
Executive Compensation Analysis
The Neuroendocrine Tumor Research Foundation reports 0% officer compensation across all available filings, indicating that no salaries or benefits are paid to its officers, which is highly unusual for an organization of its size with assets exceeding $21 million.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Neuroendocrine Tumor Research Foundation's IRS 990 filings:
- Inconsistent revenue streams with significant year-over-year fluctuations
- Expenses exceeded revenue in multiple recent periods (e.g., 2023, 2022, 2019, 2018, 2017), indicating reliance on reserves or prior surpluses.
Strengths
The following positive indicators were identified for Neuroendocrine Tumor Research Foundation:
- Zero reported officer compensation across all filings, indicating strong commitment to mission spending.
- Substantial and growing asset base ($21,377,613 latest) provides long-term financial stability.
- Consistent IRS 990 filing history demonstrates transparency.
- Strong program focus implied by lack of executive compensation.
Frequently Asked Questions about Neuroendocrine Tumor Research Foundation
Is Neuroendocrine Tumor Research Foundation a legitimate charity?
Based on AI analysis of IRS 990 filings, Neuroendocrine Tumor Research Foundation (EIN: 201945347) some concerns. Mission Score: 92/100. 2 red flags identified, 4 strengths noted.
How does Neuroendocrine Tumor Research Foundation spend its money?
Neuroendocrine Tumor Research Foundation directs 90% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Neuroendocrine Tumor Research Foundation tax-deductible?
Neuroendocrine Tumor Research Foundation is registered as a tax-exempt nonprofit (EIN: 201945347). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Neuroendocrine Tumor Research Foundation CEO make?
Neuroendocrine Tumor Research Foundation's highest-compensated officer earns $21 annually. The organization reported $5.3M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
What percentage of Neuroendocrine Tumor Research Foundation's spending goes to programs?
Neuroendocrine Tumor Research Foundation directs 90% to programs, 3% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Neuroendocrine Tumor Research Foundation compare to similar nonprofits?
With a transparency score of 92/100 (Excellent), Neuroendocrine Tumor Research Foundation is above average for NTEE category G123 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Neuroendocrine Tumor Research Foundation located?
Neuroendocrine Tumor Research Foundation is headquartered in Quincy, Massachusetts and files with the IRS under EIN 201945347. It is classified under NTEE code G123.
How many years of IRS 990 filings does Neuroendocrine Tumor Research Foundation have?
Neuroendocrine Tumor Research Foundation has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $5.3M in total revenue.
Is the Neuroendocrine Tumor Research Foundation financially stable?
Yes, despite some years where expenses exceeded revenue (e.g., 2023, 2022), the organization maintains substantial assets ($21,377,613 in the latest filing) which provide a strong financial buffer.
How does the organization manage executive compensation?
The organization reports 0% officer compensation in all available IRS 990 filings, meaning no salaries or benefits are paid to its officers.
What is the trend in the organization's revenue?
Revenue has been highly variable, ranging from a low of $2,178,575 in 2016 to a high of $17,040,511 in 2015, and $8,207,303 in 2021, indicating reliance on significant, possibly irregular, contributions.
Does the organization spend efficiently?
The absence of officer compensation strongly suggests high spending efficiency, as more funds are likely directed towards program services rather than executive overhead.
Filing History
IRS 990 filing history for Neuroendocrine Tumor Research Foundation showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Neuroendocrine Tumor Research Foundation's revenue has grown by 186.9%, moving from $1.1M to $3.2M. Total assets increased by 1091.2% over the same period, from $1.7M to $20.6M. Total functional expenses rose by 200.7%, from $1.2M to $3.6M. In its most recent filing year (2023), Neuroendocrine Tumor Research Foundation reported a deficit of $384K, with expenses exceeding revenue. The organization holds $5.1M in liabilities against $20.6M in assets (debt-to-asset ratio: 24.7%), resulting in net assets of $15.5M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $3.2M | $3.6M | $20.6M | $5.1M | — | View 990 |
| 2022 | $3.1M | $3.5M | $20.5M | $6.5M | — | — |
| 2021 | $8.2M | $5.4M | $26.6M | $7.8M | — | View 990 |
| 2020 | $4.7M | $4.0M | $23.8M | $8.4M | — | View 990 |
| 2019 | $5.2M | $6.0M | $22.3M | $9.0M | — | View 990 |
| 2018 | $4.6M | $5.7M | $19.1M | $6.7M | — | View 990 |
| 2017 | $2.3M | $6.3M | $18.8M | $4.5M | — | View 990 |
| 2016 | $2.2M | $2.1M | $19.2M | $1.5M | — | View 990 |
| 2015 | $17.0M | $1.2M | $18.9M | $1.2M | — | View 990 |
| 2014 | $3.0M | $2.1M | $4.0M | $2.2M | — | View 990 |
| 2013 | $2.3M | $2.0M | $2.7M | $1.8M | — | View 990 |
| 2012 | $2.4M | $2.0M | $1.9M | $1.3M | — | View 990 |
| 2011 | $1.1M | $1.2M | $1.7M | $1.4M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $3.2M, expenses of $3.6M, and assets of $20.6M (revenue +3.9% year-over-year).
- 2022: Revenue of $3.1M, expenses of $3.5M, and assets of $20.5M (revenue -62.5% year-over-year).
- 2021: Revenue of $8.2M, expenses of $5.4M, and assets of $26.6M (revenue +76.5% year-over-year).
- 2020: Revenue of $4.7M, expenses of $4.0M, and assets of $23.8M (revenue -11.0% year-over-year).
- 2019: Revenue of $5.2M, expenses of $6.0M, and assets of $22.3M (revenue +13.3% year-over-year).
- 2018: Revenue of $4.6M, expenses of $5.7M, and assets of $19.1M (revenue +101.1% year-over-year).
- 2017: Revenue of $2.3M, expenses of $6.3M, and assets of $18.8M (revenue +5.2% year-over-year).
- 2016: Revenue of $2.2M, expenses of $2.1M, and assets of $19.2M (revenue -87.2% year-over-year).
- 2015: Revenue of $17.0M, expenses of $1.2M, and assets of $18.9M (revenue +469.1% year-over-year).
- 2014: Revenue of $3.0M, expenses of $2.1M, and assets of $4.0M (revenue +31.8% year-over-year).
- 2013: Revenue of $2.3M, expenses of $2.0M, and assets of $2.7M (revenue -5.0% year-over-year).
- 2012: Revenue of $2.4M, expenses of $2.0M, and assets of $1.9M (revenue +114.7% year-over-year).
- 2011: Revenue of $1.1M, expenses of $1.2M, and assets of $1.7M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Neuroendocrine Tumor Research Foundation:
Data Sources and Methodology
This transparency report for Neuroendocrine Tumor Research Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.